Abstract:Background The microRNA miR-221-3p has previously been found to be an underlying biomarker of pancreatic cancer. However, the mechanisms of miR-221-3p underlying its role in pancreatic cancer pathogenesis, proliferation capability, invasion ability, drug resistance and apoptosis and the clinicopathological value of miR-221-3p have not been thoroughly studied. Methods Based on microarray and miRNA-sequencing data extracted from Gene Expression Omnibus (GEO), The Cancer Genome Atlas (TCGA), relevant literature, and real-time quantitative PCR (RT-qPCR), we explored clinicopathological features and the expression of miR-221-3p to determine its clinical effect in pancreatic cancer. Proliferation, migration, invasion, apoptosis and in vitro cytotoxicity tests were selected to examine the roles of mir-221-3p. In addition, several miR-221-3p functional analyses were conducted, including Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG) and Protein-protein interaction (PPI) network analyses, to examine gene interactions with miR-221-3p. Results The findings of integrated multi-analysis revealed higher miR-221-3p expression in pancreatic cancer tissues and blood than that in para-carcinoma samples (SMD of miR-221-3p: 1.52; 95% CI 0.96, 2.08). MiR-221-3p is related to survival both in pancreatic cancer and pancreatic ductal adenocarcinoma patients. Cell experiments demonstrated that miR-221-3p promotes pancreatic cancer cell proliferation capability, migration ability, invasion ability, and drug resistance but inhibits apoptosis. Further pancreatic cancer bioinformatics analyses projected 30 genes as the underlying targets of miR-221-3p. The genes were significantly distributed in diverse critical pathways, including microRNAs in cancer, viral carcinogenesis, and the PI3K-Akt signalling pathway. Additionally, PPI indicated four hub genes with threshold values of 5: KIT, CDKN1B, RUNX2, and BCL2L11. Moreover, cell studies showed that miR-221-3p can inhibit these four hub genes expression in pancreatic cancer. Conclusions Our research revealed that pancreatic cancer expresses a high-level of miR-221-3p, indicating a potential miR-221-3p role as a prognosis predictor in pancreatic cancer. Moreover, miR-221-3p promotes proliferation capacity, migration ability, invasion ability, and drug resistance but inhibits apoptosis in pancreatic cancer. The function of miR-221-3p in the development of pancreatic cancer may be mediated by the inhibition of hub genes expression. All these results might provide an opportunity to extend the understanding of pancreatic cancer pathogenesis.

Clinical Value of Mir-101-3p and Biological Analysis of Its Prospective Targets in Breast Cancer: A Study Based on the Cancer Genome Atlas (TCGA) and Bioinformatics.

Identification of Mir-101-3p Targets and Functional Features Based on Bioinformatics, Meta-Analysis and Experimental Verification in Hepatocellular Carcinoma.

Expression And Potential Molecular Mechanisms Of Mir-204-5p In Breast Cancer, Based On Bioinformatics And A Meta-Analysis Of 2,306 Cases

MicroRNA-3613-3p Functions As a Tumor Suppressor and Represents a Novel Therapeutic Target in Breast Cancer.

MiR-512-3p Expression Pattern and Function in Breast Cancer

Diagnostic Value of Strand‐specific Mirna‐101‐3p and Mirna‐101‐5p for Hepatocellular Carcinoma and a Bioinformatic Analysis of Their Possible Mechanism of Action

Prognostic Implications of Decreased Microrna-101-3p Expression in Patients with Non-Small Cell Lung Cancer

An Integrated Bioinformatics Analysis to Investigate the Targets of Mir-133A-1 in Breast Cancer

MicroRNA-221-3p is Related to Survival and Promotes Tumour Progression in Pancreatic Cancer: a Comprehensive Study on Functions and Clinicopathological Value

The Clinical Value of Mir‐193a‐3p in Non‐small Cell Lung Cancer and Its Potential Molecular Mechanism Explored in Silico Using RNA‐sequencing and Microarray Data

MicroRNA-101 Inhibits Growth, Proliferation and Migration and Induces Apoptosis of Breast Cancer Cells by Targeting Sex-Determining Region Y-Box 2

Down-regulation of Microrna-144-3p and Its Clinical Value in Non-Small Cell Lung Cancer: a Comprehensive Analysis Based on Microarray, Mirna-Sequencing, and Quantitative Real-Time PCR Data

Genetic Alteration and Prospective Signaling Pathways of Mir-517 A-3 P in Bladder Cancer : a Study Based on Mirna Sequencing Data and Bioinformatics Methods

Diagnostic Value Of Circulating Mir-155, Mir-21, And Mir-10b As Promising Biomarkers In Human Breast Cancer

Deregulated Expression of Mir-21, Mir-143 and Mir-181A in Non Small Cell Lung Cancer is Related to Clinicopathologic Characteristics or Patient Prognosis

Tumor-promoting Properties of Mir-8084 in Breast Cancer Through Enhancing Proliferation, Suppressing Apoptosis and Inducing Epithelial–mesenchymal Transition

Mir-143-5p Suppresses Breast Cancer Progression by Targeting the HIF-1-related GLUT1 Pathway

Potential Targets and Clinical Value of Mir-490-5p in Hepatocellular Carcinoma: a Study Based on TCGA, Qrt-Pcr and Bioinformatics Analyses.

Identification of Serum miR-501-3p and miR-338-3p as Novel Diagnostic Biomarkers for Breast Cancer and Their Target Genes Associated with Immune Infiltration

Expression Level and Potential Target Pathways of Mir-1-3p in Colorectal Carcinoma Based on 645ï¿½cases from 9 Microarray Datasets

Microrna Mir-21 Overexpression in Human Breast Cancer is Associated with Advanced Clinical Stage, Lymph Node Metastasis and Patient Poor Prognosis